Recent News

• 11.03.2025 - EyePoint Announces Participation at Upcoming Investor Conferences
• 10.29.2025 - EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
• 10.16.2025 - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 10.15.2025 - EyePoint Announces Pricing of Public Offering
• 10.14.2025 - EyePoint Announces Proposed Public Offering of Common Stock
• 10.14.2025 - EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
• 09.16.2025 - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 09.16.2025 - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 09.16.2025 - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 09.03.2025 - Cantor Global Healthcare Conference

Recent Filings

• 10.17.2025 - EX-99.1 EX-99.1
• 10.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.17.2025 - 8-K Current report
• 10.16.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.15.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 10.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.14.2025 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 10.14.2025 - 8-K Current report
• 10.14.2025 - EX-99.1 EX-99.1
• 09.22.2025 - 4 Statement of changes in beneficial ownership of securities